NCT01561521View on ClinicalTrials.gov

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AKF-1

1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period

DRUG

AKF-1

1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period

DRUG

AKF-1

1 drop 0% in each eye at 2 separate times during a 14 day period

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

Akorn, Inc.

INDUSTRY

NCT01561521 - An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter